Data presented at ESMO highlight the promising efficacy of olomorasib in combination with standard-of-care immunotherapy with or without chemotherapy in first-line advanced KRAS G12C-mutant non-small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results